Università degli Studi di Milano Dipartimento di Scienze Farmaceutiche “Pietro Pratesi” Alessandro Pedretti GriDock: An MPI-based software for virtual.

Slides:



Advertisements
Similar presentations
SOMA2 – Drug Design Environment. Drug design environment – SOMA2 The SOMA2 project Tekes (National Technology Agency of Finland) DRUG2000 program.
Advertisements

Alessandro Pedretti A new distributed paradigm for parallel computing UNIVERSITÁ DEGLI STUDI DI MILANO Facoltà di Scienze del Farmaco.
Università degli Studi di Milano Dipartimento di Scienze Farmaceutiche “Pietro Pratesi” Alessandro Pedretti Protein modeling by fragmental approach: connecting.
AutoDock 4 and AutoDock Vina -Brief Intruction
Overview of Key ICM Features NIBR - Emeryville July
Improving enrichment rates A practical solution to an impractical problem Noel O’Boyle Cambridge Crystallographic Data Centre
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Computational Drug Design Apr 2010 Postgrad course on Comp Chem Noel M. O’Boyle.
Molecular dynamics refinement and rescoring in WISDOM virtual screenings Gianluca Degliesposti University of Modena and Reggio Emilia Molecular Modelling.
1 PharmID: A New Algorithm for Pharmacophore Identification Stan Young Jun Feng and Ashish Sanil NISSMPDM 3 June 2005.
Receptor-based virtual screening Lab version 2. Virtual screening Goal: identify ligands that tightly bind to a protein Requirements: a computer database.
Docking molecules with Vina
BL5203: Molecular Recognition & Interaction Lecture 5: Drug Design Methods Ligand-Protein Docking (Part I) Prof. Chen Yu Zong Tel:
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Molecular Docking Using GOLD Tommi Suvitaival Seppo Virtanen S Basics for Biosystems of the Cell Fall 2006.
Protein-protein and Protein- ligand Docking The geometric filtering.
In Silico Design of Selective Estrogen Receptor Modulators from Triazoles and Imines Joey Salisbury Dr. John C. Williams Small Molecules/Large Molecules.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Homology Modeling David Shiuan Department of Life Science and Institute of Biotechnology National Dong Hwa University.
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Computer-Assisted Drug Design (1) i)Random Screening ii)Lead Development and Optimization using Multivariate Statistical Analyses. iii)Lead Generation.
Combinatorial Chemistry and Library Design
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Molecular docking and QSAR analysis: a combined approach applied to FTase inhibitors and  1a -AR antagonists Università degli Studi di Milano Giulio Vistoli,
Using the WS-PGRADE Portal in the ProSim Project Protein Molecule Simulation on the Grid Tamas Kiss, Gabor Testyanszky, Noam.
Alessandro Pedretti Virtual screening and collaborative computing: a new frontier in drug discovery UNIVERSITÁ DEGLI STUDI DI MILANO Facoltà di Scienze.
A genetic algorithm for structure based de-novo design Scott C.-H. Pegg, Jose J. Haresco & Irwin D. Kuntz February 21, 2006.
Application of e-infrastructure to real research.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
High-Throughput Virtual Molecular Docking: Hadoop Implementation of AutoDock4 on a Private Cloud Sally R. Ellingson Graduate Research Assistant Center.
G. Terstyanszky, T. Kukla, T. Kiss, S. Winter, J.: Centre for Parallel Computing School of Electronics and Computer Science, University of.
Protein Molecule Simulation on the Grid G-USE in ProSim Project Tamas Kiss Joint EGGE and EDGeS Summer School.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
SimBioSys Inc.© Slide #1 Enrichment and cross-validation studies of the eHiTS high throughput screening software package.
Altman et al. JACS 2008, Presented By Swati Jain.
Rational Drug Design : HIV Integrase. A process for drug design which bases the design of the drug upon the structure of its protein target. 1.Structural.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Avian Flu Data Challenge Hsin-Yen Chen ASGC 29 Aug APAN24.
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Computer-aided drug discovery (CADD)/design methods have played a major role in the development of therapeutically important small molecules for several.
R L R L L L R R L L R R L L water DOCKING SIMULATIONS.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
GRIDP: Web-enabled Drug Discovery Is there any way I can use computational tools to reduce the number of molecules I have to screen to a manageable number,
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
CoMFA Study of Piperidine Analogues of Cocaine at the Dopamine Transporter: Exploring the Binding Mode of the 3  -Substituent of the Piperidine Ring Using.
Molecular mechanics Classical physics, treats atoms as spheres Calculations are rapid, even for large molecules Useful for studying conformations Cannot.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Improving compound–protein interaction prediction by building up highly credible negative samples Toward more realistic drug-target interaction predictions.
Docking and Virtual Screening Using the BMI cluster
Molecular Modeling in Drug Discovery: an Overview
FESR Consorzio COMETA - Progetto PI2S2 Molecular Modelling Applications Laura Giurato Gruppo di Modellistica Molecolare (Prof.
HP-SEE In the search of the HDAC-1 inhibitors. The preliminary results of ligand based virtual screening Ilija N. Cvijetić, Ivan O. Juranić,
Page 1 Molecular Modeling Service in Profacgen. Page 2 The three-dimensional structure of a protein provides essential information about its biological.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Dhanvantari GenOME to hit
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Protein Structure Prediction and Protein Homology modeling
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Virtual Screening.
“Structure Based Drug Design for Antidiabetics”
Università degli Studi di Milano
Ligand Docking to MHC Class I Molecules
Reporter: Yu Lun Kuo (D )
Cheminformatics Basics
Protein structure prediction
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Presentation transcript:

Università degli Studi di Milano Dipartimento di Scienze Farmaceutiche “Pietro Pratesi” Alessandro Pedretti GriDock: An MPI-based software for virtual screening in drug discovery

What is the virtual screening ? The virtual screening (VS) is a computational approach that can be used in drug discovery processes to find new hit compounds. It can be compared to the High-throughput screening (HTS) that is a true experimental approach. Database of molecules Database filter Hit compounds Virtual screening Set of molecules Experimental assay Hit compounds High-throughput screening Database of molecules Database filter Hit compounds Virtual screening

The database of molecules The database must contain molecules that are available in the real world or synthetically accessible in easy way. The pharmaceutical industries have got databases built trough the years from researches in some different fields. Some databases are publicly available and provided by chemical compound resellers (AKos, Asinex, TimTec, etc) or by non-profit institutions (Kyoto University, NCI, University of Padua, etc). The database must contain a large number of molecules in order to do an exhaustive exploration of the chemical space.

The database filter The database filter does the virtual test to check if a molecule could be bioactive or not. The kind of filter allows to classify the virtual screening approaches in: Ligand-based The 3D structure of the biological target is unknown and a set of geometric rules and/or physical-chemical properties (pharmacophore model) obtained by QSAR studies are used to screen the database. Structure-based It involves molecular docking calculations between each molecule to test and the biological target (usually a protein). To evaluate the affinity a scoring function is applied. The 3D structure of the target must be known.

Molecular docking Ligand Receptor + Ligand – receptor complex Docking software The complex quality is evaluated by the score.

GriDock – Main features GriDock is a software developed to perform structure-based virtual screenings. It’s a front-end to the well known AutoDock software, developed by D.S. Goodsel and A.J. Olson. It uses VEGA command-line software to perform file format conversion, database extraction and molecular property calculations. AutoDock 4 + VEGA GriDock Virtual screening Highly portable C++ code (Linux 32 and 64 bit, Windows 32 and 64 bit). It can take full advantages of multi-CPUs/cores systems and GRID-based architectures through its parallel design.

How GriDock works Molecular docking. Score calculation. Database of molecules VEGA Ligand – receptor complexes AutoDock 4 Score analysis Output files Calculation of the molecular properties. Input file generation (PDBQT). Receptor coord. + maps Receptor coord. + maps

How VEGA works with GriDock Database of molecules Hydrogens add Potential attribution Property calculation Calculation of charges Search of flexible torsions Conversion to PDBQT to AutoDock 4 AMBER force field Gasteiger-Marsili method

GriDock multi-threaded version GriDock main thread VEGA AutoDock 4 Thread 1 VEGA AutoDock 4 Thread 2 VEGA AutoDock 4 Thread n Database Receptor Output files* Thread loop Symmetric multiprocessing (SMP) provided by pthread library or Windows APIs Log file (gridock_DATE.log). CSV file containing the list of complexes ranked by docking score. Zip file containing the output complexes generated by AutoDock 4. Mutex controlled access

GriDock MPI version Output files GriDock MPI master node Database Receptor Database Receptor Database Receptor VEGA AutoDock 4 Node 2 VEGA AutoDock 4 Node n Node loop MPI VEGA AutoDock 4 Node 1

GriDock input requirements To perform a virtual screening with GriDock, you need: The 3D structure of the biological target. -Protein Data Bank ( -Homology modeling. The 3D maps of the active site generated by AutoGrid 4 -AutoDockTools / MGLTools ( -VEGA ZZ ( One or more databases of 3D structures in SDF or Zip format. Ligand.Info: Small-Molecule Meta-Database ( MMsINC ( ZINC (

The Citrus tristeza virus case The Citrus tristeza virus (CTV) is a positive single stranded RNA virus that causes a serious pathology of the citruses. Any treatment to save the infected plants is unknown. A possible therapeutic target could be the RNA-dependent-RNA polymerase (RdRp) involved in the virus replication. ssRNA (+) – 5’ prot.mRNA ProteaseTranslation Early protein RdRp prot. Other proteins Protease (-)RNA Replicative complex Structural proteins Virions Infected cell Translation

The RdRp model The crystal structure doesn’t exist and a homology modeling procedure was performed: Rough 3D structure Primary structure SwissProt Q2XP15 Folding prediction Fugue To the refinement workflow To the refinement workflow VEGA ZZ + NAMD RdRp model

Model refinement Missing residues Side chains add Hydrogens add Energy minimization Model ready for the screening Model ready for the screening Rough model VEGA ZZ + NAMD steps conjugate gradients Structure check Ramachandran plot

Calculation of the grid maps AutoDock requires pre-calculated grid maps to evaluate the total interaction energy between the ligand and the target macromolecule. To do it, we used the script included in the VEGA ZZ package: Mapping the active site RdRp structure Potential attribution Calculation of charges Apolar hydrogens remove PDBQT file AutoGrid 4 run Grid map files Script file: AutoDock/Receptor.c

Considered databases All test databases in SDF format were downloaded from ChemBank ChemPDB KEGG Ligand Anti-HIV NCI Drug/likeness NCI Not annotate NCI AKos GmbH Asinex Ltd. The total number of docked ligands is: ~1,000,000

Test system Tyan Transport VX50 # 8 AMD Opteron 875 dual core 2.4 GHz. 8 Gb Ram Gb SATA hard disk. Linux 64 bit (CentOS 4). 40,000 ligands/day.

Preliminary results The top ranked ligands contains in their structure one or more sulfurs. Sulfonic acid derivatives. These compounds are know to be potent inhibitors of the HIV reverse transcriptase. Some of them are naphtalen polysulfonic acids developed as Anti-HIV (Anti-HIV NCI database).

Conclusions We developed a new parallel structure-based virtual screening software able to run on both multi-CPU and GRID systems. The complete model of the RNA-dependent-RNA-polymerase of Citrus Tristeza Virus was obtained to perform a virtual screening study. Screening ~1,000,000 ligands, potential RdRp inhibitors were found. These molecules contains sulfur atoms and, more in details, multiple sulfonic acid moieties. Some of them are included in the Anti-HIV class. To complete the study, the activity of the found molecules must be experimentally confirmed by biological assays.

Acknowledgments Giulio Vistoli Cristina Marconi Alessandro Lombardo Santo Motta Francesco Pappalardo Emilio Mastriani